From: Clinical implication of HLA class I expression in breast cancer
 |  | Univariate analysis | Multivariable analysis | ||
---|---|---|---|---|---|
 |  | Disease free interval | Disease free interval | ||
Variables | Categories | HR (95% confidence interval) | p value | HR (95% confidence interval) | p value |
Tumor size | T3+T4 (vs T1+T2) | 0.249 (0.120 - 0.514) | P = 0.0020 | 0.459 (0.212 - 0.995) | P = 0.0485 |
Nodal involvement | N1 (vs N0) | 0.148 (0.068 - 0.324) | P < 0.0001 | 0.230 (0.092 - 0.574) | P = 0.0016 |
Estrogen receptor | Positive (vs negative) | 1.656 (0.872 - 3.146) | 0.1231 | Â | Â |
Progesterone receptor | Positive (vs negative) | 1.932 (1.019 - 3.664) | P = 0.0437 | 2.168 (1.109 - 4.240) | P = 0.0237 |
Lymphatic invasion | Positive (vs negative) | 0.246 (0.117 - 0.521) | P = 0.0020 | 0.871 (0.346 - 2.194) | 0.7689 |
Vascular invasion | Positive (vs negative) | 0.184 (0.094 - 0.361) | P < 0.0001 | 0.423 (0.198 - 0.904) | P = 0.0264 |
HER2 receptor | Positive (vs negative) | 0.653 (0.272 - 1.565) | 0.3390 | Â | Â |
HLA class I expression | Negative (vs positive) | 2.513 (1.050 - 6.012) | P = 0.0384 | 1.691 (0.696 - 4.110) | 0.2462 |